Global Renal Disease Therapeutics Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Application, Treatment Devices, and Region – Industry Forecast (2024 to 2029)

Updated On: January, 2024
ID: 1217
Pages: 175

Global Renal Disease Therapeutics Market Size (2024 to 2029)

The global renal disease therapeutics market size is predicted to grow at an impressive CAGR between 2024 to 2029.

Renal diseases are progressive loss of the proper functioning of the kidneys. Over a more extended period, the associated renal system fuels the market because of its high incidence rate worldwide. The kidneys have many life-sustaining functions, such as cleansing the blood by filtering waste products and excess fluid, regulating blood pressure, and maintaining the balance of salt and minerals. When kidney failure occurs, they ultimately lose their vital function, which is fatal. Kidney damage/failure can be developed acutely (AKI) and over time (CKD). Three types of treatment are most prevalent to cure kidney failure prescription medications, surgical intervention, and dialysis (peritoneal dialysis, hemodialysis, and continuous renal replacement therapy), which are frequently used in combination to treat a single case of renal failure.

MARKET DRIVERS

Some of the key drivers of the renal disease therapeutics market are the increasing aging population, growing awareness of both acute and chronic kidney disease, an increasing number of individuals with insurance due to the Affordable Care Act, an Increasing Diabetic Population, and rising demand for advanced diagnostics and therapeutics for the disease.

MARKET RESTRAINTS

Disparities of Renal Transplant Therapy, the expiration of patents of some of the branded drugs for late-stage CKD, and changing reimbursement scenarios in some significant countries, Negative Societal Effects, are the restraints that hinder the growth of the market.

REPORT COVERAGE

REPORT METRIC

DETAILS

Market Size Available

2023 to 2029

Base Year

2023

Forecast Period

2024 to 2029

Segments Covered

By Application Mode, Treatment and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities

Regions Covered

North America, Europe, APAC, Latin America, Middle East & Africa

Market Leaders Profiled

Amgen Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, Hoffmann-La Roche Inc., Shire Inc., Fresenius Medical Care, Baxter International and Davita Healthcare Partners

 

REGIONAL ANALYSIS

Geographically, the North American market is predicted to dominate the global renal disease therapeutics market during the forecast period. Europe comes next. However, the Asia-Pacific is projected to show the highest CAGR over the forecast period due to an increasing number of high blood pressure and diabetic patients and a growing demand for advanced diagnostics and therapeutics in the region.

KEY PLAYERS IN THE RENAL DISEASE THERAPEUTICS MARKET

Companies leading the global renal disease therapeutics market profiled in the report are Amgen Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, Hoffmann-La Roche Inc., Shire Inc., Fresenius Medical Care, Baxter International, and Davita Healthcare Partners.

DETAILED SEGMENTATION OF THE GLOBAL RENAL DISEASE THERAPEUTICS MARKET

This research report on the global renal disease therapeutics market has been segmented and sub-segmented based on application mode, treatment, and region.

By Application Mode

  • Kidney Stone Disease
  • End-Stage Kidney Disease
  • Kidney Failure
  • Chronic Kidney Disease
  • Hypertension
  • Diabetes
  • Anemia

By Treatment

  • Dialysis Equipment
  • Renal Denervation Devices
  • Wearable Artificial Kidney Device
  • Distal Embolic Protection Devices

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • The Middle East and Africa

Please wait. . . . Your request is being processed

Frequently Asked Questions

What are the factors driving the growth of the renal disease therapeutics market?

The increasing prevalence of kidney diseases, the growing aging population, and advancements in medical technology are the key factors driving the growth of the renal disease therapeutics market.

What are the challenges faced by the renal disease therapeutics market?

The high cost of renal disease therapeutics, lack of effective treatments for some types of kidney diseases, and stringent regulatory requirements are some of the challenges faced by the renal disease therapeutics market.

Who are the key players in the renal disease therapeutics market?

Some of the key players in the renal disease therapeutics market include Amgen Inc., AstraZeneca plc, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, and Pfizer Inc.

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1800

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample